Selskabets formål er at udvikle nye lægemidler og dermed beslægtet virksomhed.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 20.6 mio. | -4.8 mio. | 97.6 mio. | 79.5 mio. | 14 | |
CVR: 33062214
Previous names: CONCIT PHARMA ApS, CONTERA PHARMA ApS
Compared to 998 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Mi Chung Ahn joined the board
Jee Hun Kim joined the board
WooHyun Lee left the board
Mi Chung Ahn left the board
Companies in the same industry and area
companydata.dk